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Mitochondrial diseases, caused by respiratory chain (RC) deficiency, encompass a wide range of clinical manifestations. They mainly affect organs with high-energy requirements, such as the brain. They are also increasingly recognized as causes of refractory epilepsy, which is consistently associated with progressive neurologic deterioration.[@bib1] Genetic diagnosis of RC disorders remains challenging because of the involvement of mitochondrial DNA (mtDNA) or nuclear DNA. In addition, RC dysfunction might be the primary cause of symptoms or secondary to other disorders. The Krebs cycle is intimately linked to the RC, and Krebs cycle defects are among the diseases that mimic or cause RC deficiencies. However, human diseases associated with defects in the Krebs cycle are very rare, putatively because of the cycle's essential function in cellular energy metabolism.

Here, we show that mutations in *MDH2* (MIM: [154100](154100){#intref0010}), encoding the Krebs cycle enzyme mitochondrial malate dehydrogenase (MDH), are responsible for severe neurological manifestations in children. We report bi-allelic *MDH2* variants in three unrelated subjects presenting with an early-onset mitochondrial phenotype comprising generalized hypotonia, psychomotor delay, and refractory epilepsy. All affected individuals were independently identified by whole-exome sequencing (WES). Two of them were "matched" by GeneMatcher, a web-based tool for connecting researchers and clinicians with shared interests in identical genes.[@bib2] The third subject was identified independently and was matched within GENOMIT, an European network of researchers with an interest in mitochondrial genetic disorders.

Informed consent for diagnostic and research studies was obtained for all subjects in accordance with the Declaration of Helsinki protocols and was approved by local ethics committees. Subject 1 (S1) in family F (F1:II.2) is the second, male child of healthy, non-consanguineous French parents. Pregnancy and birth were both unremarkable. At 5 months of age, he presented with marked hypotonia and absence of head control (detailed in [Table 1](#tbl1){ref-type="table"}). His overall disease course was characterized by psychomotor delay with partial epileptic seizures that rapidly evolved toward refractory myoclonic epilepsy, failure to thrive, and obstinate constipation. At 3 years of age, growth remained problematic despite tube feeding through percutaneous gastrostomy, and he presented with generalized muscle weakness (predominant in the lower limbs) with marked muscle atrophy, severe hypotonia, and abnormal movements with dyskinesia. At 4 years, retinitis pigmentosa was noted. Brain magnetic resonance imaging (MRI) showed nonspecific findings including atrophy of the anterior part of the corpus callosum, delayed myelination of the frontal white matter, and cortical, frontal, and parietal atrophy ([Figure S1](#mmc1){ref-type="supplementary-material"}). The clinical phenotype, combined with elevated lactate concentrations in both plasma and cerebrospinal fluid (CSF), was evocative of a mitochondrial disease. A slight decrease in complex V activity was found in the liver, whereas muscle tissue showed no signs of mitochondrial dysfunction ([Tables S1](#mmc1){ref-type="supplementary-material"}A and S1B). We observed no evidence of mtDNA rearrangements in either muscle or liver tissue and excluded mtDNA point mutations by using targeted next-generation sequencing protocols. WES via previously described methodologies and bioinformatic filtering pipelines[@bib3] identified compound-heterozygous missense variants in *MDH2* (GenBank: [NM_005918.3](ncbi-n:NM_005918.3){#intref0015}): c.398C\>T (p.Pro133Leu) and c.620C\>T (p.Pro207Leu). Familial segregation studies showed that the c.398C\>T variant was inherited from the father (F1:I.1) and the c.620C\>T variant was inherited from the mother (F1:I.2), whereas a healthy sister (F1:II.1) was a heterozygous carrier of the paternal (c.398C\>T) variant only ([Figure 1](#fig1){ref-type="fig"}A).

Subject 2 (S2) (F2:II.1) was the first male child of healthy, unrelated Dutch parents (F2:I.1 and I.2). He was born after an uncomplicated pregnancy and presented during the neonatal period with obstinate constipation and positional preference of his head ([Table 1](#tbl1){ref-type="table"}). At 2 months, he developed refractory epilepsy with generalized tonic seizures and epileptic spasms but had normal brain MRI ([Figure S1](#mmc1){ref-type="supplementary-material"}). At 6 months, examination showed axial hypotonia, head lag, and developmental delay in the absence of failure to thrive. Repeat brain MRI showed delayed myelination of the genu of the corpus callosum and cortical and subcortical atrophy of the frontal lobes ([Figure S1](#mmc1){ref-type="supplementary-material"}). Examination at 1 year of age demonstrated muscle weakness, and he was not able to sit. Ophthalmologic examination was normal. Metabolic screening showed elevated lactate concentrations in both blood and CSF ([Table 1](#tbl1){ref-type="table"}). In a clinical examination at 20 months of age, he presented with coughing, vomiting, tachypnea, and impaired consciousness associated with severe metabolic acidosis (blood pH = 6.97 \[normal 7.4\] and plasma lactate concentration = 9.0 mmol/l \[normal range \< 2.20mmol/l\]). The urinary organic acid profile was highly abnormal with strongly increased excretion of ketone bodies, lactate, pyruvate, malate, fumarate, and 3-methylglutaconic acid. During the course of his hospital admission, he developed severe pulmonary hypertension requiring resuscitation, although a thorough cardiac evaluation revealed no underlying heart defect. He died 1 week later upon withdrawal of ventilatory support. Molecular screening, including mtDNA sequencing, *POLG* sequencing, and epilepsy gene-panel analysis failed to establish a molecular diagnosis. WES identified two heterozygous *MDH2* variants: a paternally inherited c.398C\>T (p.Pro133Leu) missense variant, which was also found in S1, and a maternally inherited c.596delG (p.Gly199Alafs^∗^10) nonsense variant ([Figure 1](#fig1){ref-type="fig"}A).

Independently, *MDH2* was prioritized by GenePROF, a machine-learning algorithm we have recently developed to prioritize potential disease-causing mutations according to variant frequency and functional gene annotation obtained from molecular-pathway databases (manuscript in preparation). GenePROF ranked *MDH2* as the most likely disease-causing gene for an unrelated affected subject (S3, F3:II.1) who also carries a maternally inherited c.398C\>T (p.Pro133Leu) *MDH2* variant ([Figure 1](#fig1){ref-type="fig"}A). This individual is also heterozygous for a de novo c.109G\>A (p.Gly37Arg) variant that is not present in either parent (F3:I.1 or I.2). Paternity was confirmed by genotype analysis of seven informative microsatellites. This child was born at term to healthy, unrelated French parents and presented with severe hypotonia, macrocephaly, macrosomia, and two supernumerary nipples ([Table 1](#tbl1){ref-type="table"}). His overall disease course was characterized by psychomotor delay with refractory epilepsy, dystonia, and failure to thrive despite tube feeding through percutaneous gastrostomy. Lactate was elevated in blood (2.8 mmol/L \[normal range \< 2.20mmol/L\]), consistent with a lactate peak on magnetic resonance spectroscopy (MRS) (data not shown). Marked cerebral and cerebellar atrophy were observed on brain MRI at the age of 4 years ([Figure S1](#mmc1){ref-type="supplementary-material"}). A slight decrease in complex V activity was found in muscle tissue ([Table S1](#mmc1){ref-type="supplementary-material"}C).

Multiple lines of evidence provided by bioinformatics analyses support the pathogenicity of the missense variants identified in these subjects. The c.620C\>T variant detected in S1 was absent from public databases, whereas the c.109G\>A variant detected in S3 was found two times, and the c.398C\>T variant, present in all subjects, was listed seven times only in a heterozygous state in ∼120,000 alleles from the Exome Aggregation Consortium (ExAC) Browser. Additionally, the three different missense variants found in affected subjects alter highly conserved amino acid residues ([Figure 1](#fig1){ref-type="fig"}B), and bioinformatics analyses predicted these variants as pathogenic ([Table S2](#mmc1){ref-type="supplementary-material"}). The dimeric protein was co-crystallized with malate ion and nicotinamide-adenine-dinucleotide (NAD) for visualization of the structure and analysis of the structural consequences of MDH2 variants ([Figure 1](#fig1){ref-type="fig"}C). Gly37 is located in the NAD binding pocket; the mutation from this residue to arginine is likely to alter the binding of the coenzyme as a result of steric hindrance. Pro133 is located in a turn between an α helix and a β strand. Pro207 is located in a β strand. The turns are almost exclusively found on the surface of proteins and often contain proline residues that form a rigid backbone, as predicted for Pro133. On the contrary, proline tends to be excluded from β strands, but it can be situated at the ends of this motif, like for Pro207. In this case, proline imposes its own kind of secondary structure with a confined ϕ angle, creating a twist in the β strand. Thus, Pro133 and Pro207 are predicted to have structural roles by contributing to the overall architecture of MDH2. Consequently, the p.Pro133Leu and p.Pro207Leu variants might result in destabilization of protein regions necessary for functional protein folding.

We used primary fibroblast cultures established from S1 and S3 to confirm the role of *MDH2* variants in disease. Western blotting showed that MDH2 levels were not detectable in either S1 or S3 fibroblasts, supporting the notion that corresponding *MDH2* variants adversely affect the stability of the protein ([Figure 2](#fig2){ref-type="fig"}A). In addition, MDH enzymatic activity was markedly decreased in that it showed severe MDH deficiency ([Figure 2](#fig2){ref-type="fig"}B). The activity was notably lower in cells obtained from the parents of S1 (F1: I.1 and I.2, heterozygous for the c.398C\>T and c.620C\>T variants, respectively) than in control fibroblasts. This result suggests that each mutation individually has a deleterious effect. As expected from MDH function in the Krebs cycle ([Figure 2](#fig2){ref-type="fig"}C), ratios of malate and its direct precursor, fumarate, to citrate were significantly higher in S1 cells than in control fibroblasts without accumulation of the earlier Krebs cycle precursor, succinate ([Figure 2](#fig2){ref-type="fig"}D). MDH activity appeared sufficient in cells from the parents of S1 to maintain normal malate/citrate and fumarate/citrate ratios.

Next, we expressed wild-type human *MDH2* cDNA in *MDH2*-deficient S1 fibroblasts by using a lentiviral-based transduction system, leading to the restoration of both MDH2 levels and enzyme activity ([Figures 3](#fig3){ref-type="fig"}A and 3B). To definitively substantiate that the disease-segregating missense *MDH2* variants indeed cause MDH2 deficiency, we used the yeast *Saccharomyces cerevisiae* as a proven system for modeling mitochondrial-disease-causing mutations.[@bib5] In yeast, three genes encode MDH enzymes. *MDH1* codes for the mitochondrial MDH enzyme, *MDH2* codes for the cytoplasmic enzyme, and *MDH3* encodes the peroxisomal form. The human Gly37, Pro133, and Pro207 residues (corresponding to Gly30, Pro128, and Pro202, respectively, in yeast MDH1) are all conserved between the two species ([Figure 1](#fig1){ref-type="fig"}B). The expression of wild-type human *MDH2* cDNA failed to complement the absence of growth of the *mdh1Δ* yeast strain on non-fermentable medium despite a high degree of conservation (54% identity) between yeast and human proteins ([Figure 3](#fig3){ref-type="fig"}C). We evaluated whether the lack of complementation of the *mdh1Δ* strain by human MDH2 was due to a failure to import MDH2 into yeast mitochondria. To this end, we changed the MDH2 mitochondrial targeting sequence (MTS) by the first 69 amino acids of subunit 9 of the F~0~ ATPase of *Neurospora crassa* (Pre Su9), a well-characterized sequence that targets the mitochondrial matrix in yeast.[@bib6] Expression of the fusion MDH2 (Pre Su9-MDH2) allowed growth of the *mdh1Δ* cells on non-fermentable medium, indicating that the human MDH2 MTS is not recognized by yeast as a functional MTS and that once inside mitochondria, MDH2 can substitute for MDH1 (data not shown). Consequently, we introduced the amino acid changes into the yeast sequence. The *MDH1*, *mdh1*^G30R^, *mdh1*^P128L^, and *mdh1*^P202L^ constructs were transformed into the *mdh1Δ*-null mutant ([Figure 3](#fig3){ref-type="fig"}C). As expected, expression of wild-type yeast *MDH1* complemented the *mdh1Δ* strain. A clear growth defect was observed for all *mdh1Δ*/*mdh1*^mut^ strains, thus confirming the deleterious nature of the human *MDH2* variants.

Given that the Krebs cycle is intimately linked to the RC, we investigated mitochondrial RC enzyme activities in *MDH2*-deficient fibroblasts. Spectrophotometric analysis revealed no obvious abnormalities in S1 cells grown in glucose medium, but complex I activity was lower than in one of the other complexes in fibroblasts from S3 ([Table S1](#mmc1){ref-type="supplementary-material"}D). Polarographic analysis showed intact cell respiration and mitochondrial substrate oxidation in digitonin (0.004%)-permeabilized cells from both subjects ([Table S1](#mmc1){ref-type="supplementary-material"}E). Identical experiments were performed on fibroblasts grown in a glucose-free medium containing galactose as previously described;[@bib7] galactose is a carbon source that feeds the glycolytic pathway with low efficiency, and as such, cells are forced to rely predominantly on OXPHOS for ATP production. Cells with severe RC defects fail to survive under these conditions, whereas fibroblasts with a milder deficiency are able to grow.[@bib8] No significant differences were observed between S1, S3, and control cells assessed by both spectrophotometry and polarography ([Tables S1](#mmc1){ref-type="supplementary-material"}F and S1G). We also observed no decrease in OXPHOS levels in S1 cells, as judged by semiquantitative western blotting ([Figure S2](#mmc1){ref-type="supplementary-material"}A). Assessment of the mitochondrial network (by confocal microscopy using MitoTracker staining) in cells from S1 and S3 showed a typical filamentous interconnected network similar to that in control fibroblasts both in glucose ([Figure S2](#mmc1){ref-type="supplementary-material"}B) and in galactose medium (data not shown).

*MDH2* encodes the enzyme MDH, which catalyzes the reversible oxidation of malate to oxaloacetate by utilizing the NAD-NADH cofactor system in the Krebs cycle. In addition, MDH2 plays an essential role in the malate-aspartate NADH shuttle, which is the main pathway whereby reducing equivalents from cytosolic NADH are transferred to mitochondria. Enzyme deficiencies in the Krebs cycle have been rarely reported as the cause of metabolic disease presentations on the assumption that loss-of-function mutations affecting these key enzymes appear to be typically incompatible with life. To date, only recessively inherited variants in *SDH* (succinate dehydrogenase), *FH* (fumarate hydratase \[MIM: [136850](136850){#intref0020}\]), and *ACO2* (aconitase 2 \[MIM: [100850](100850){#intref0025}\]) have been associated with human disease. SDH comprises two structural subunits (SDHA and SDHB), and two additional structural components (SDHC and SDHD) and two assembly factors (SDHAF1 and SDHAF2) are required for the biogenesis of complex II (succinate-ubiquinone oxidoreductase) of the RC. Recessively inherited *SDHA* variants are mainly associated with Leigh syndrome (MIM: [256000](256000){#intref0030}), and mutations in *SDHB* (MIM: [185470](185470){#intref0035}), *SDHD* (MIM: [602690](602690){#intref0040}), and *SDHAF1* (MIM: [612848](612848){#intref0045}) are involved in severe infantile neurological presentations or cardiomyopathy associated with significant complex II deficiency.[@bib9], [@bib10], [@bib11], [@bib12] Fumarase deficiency, associated with recessively inherited *FH* variants, is a metabolic disorder characterized by neurological impairment in early childhood accompanied by encephalopathy and seizures, often leading to death in the first years of life (for a review, see Ottolenghi et al.[@bib13]). Finally, mutations in *ACO2*, encoding mitochondrial aconitase, are responsible for cerebellar-retinal degeneration in childhood.[@bib14]

Our report documents that loss-of-function mutations in *MDH2* are compatible with life and are associated with early-onset severe neurological disease, and the deleterious nature of the identified *MDH2* variants has been confirmed by functional assessment in both human cells and a yeast model. Establishing the diagnosis of MDH2 deficiency is difficult. The clinical phenotypes and elevated lactate levels observed in all three children were highly evocative of an underlying mitochondrial disorder, although brain MRI findings were non-specific. However, we observed no sign of RC deficiency or mitochondrial dysfunction in fibroblasts from S1. Only cells from S3 showed a reduced activity of complex I, emphasizing the problems associated with RC analyses, including primary and secondary effects and tissue variation. As previously suggested,[@bib15], [@bib16] functional splitting of the Krebs cycle in complementary mini-cycles might allow conversion of pyruvate to α-ketoglutarate even when there is a defect in the second half of the Krebs cycle. This would then produce reduced equivalents to sustain RC activity. In all affected individuals, levels of urinary malate and fumarate were moderately increased or normal ([Figure S3](#mmc1){ref-type="supplementary-material"}). As observed in subject fibroblasts, we saw no increase in urinary succinate, except during an episode of metabolic decompensation in S2. It is important to bear in mind that MDH2-deficient individuals can show nearly normal concentrations of urinary organic acids and that analysis has to be repeated at the time of metabolic decompensation. There are no curative treatments for subjects with MDH2 deficiency, but trial of a ketogenic diet has appeared to decrease the frequency of epileptic seizures in two children, as has already been reported in other cases of refractory epilepsy, including that of a mitochondrial origin.[@bib17], [@bib18]

Disruption of the Krebs cycle is also a hallmark of some cancers. Dominant defects associated with tumor development have been reported in three Krebs cycle enzymes: isocitrate dehydrogenase 1 (IDH1), SDH, and fumarate hydratase (FH),[@bib19], [@bib20], [@bib21] and *MDH2* was also recently identified as a pheochromocytoma and paraganglioma susceptibility gene.[@bib4] In subjects' paragangliomas, loss of heterozygosity was associated with loss of MDH2 activity, but surprisingly, this did not lead to malate accumulation. However, targeted knockdown of *MDH2* expression in HeLa cells by small hairpin RNA did lead to the accumulation of both malate and fumarate.[@bib4] Like succinate and fumarate, malate stabilizes hypoxia inducible factor 1 alpha (HIF-1α), thus triggering the hypoxia response transcriptional program.[@bib22] HIF-1α activation was found to induce transcriptional upregulation in some of the proteins participating in pyruvate metabolism, leading to PDH complex inactivation and pyruvate accumulation in the cytosol. Impairment of the PDH complex leads to a decrease in the production of NADH and FADH2, which donate electrons to the RC to complete the OXPHOS by generating ATP.[@bib23] Thus, cells develop lactic acidosis as a result of a defective PDH complex, Krebs cycle, or RC. Secondary RC deficiency could also contribute to the mitochondrial phenotypes found in our subjects.

Although the recessive *MDH2* variants identified in the affected subjects described in this study lead to a severe neurological presentation, the fact that their parents are heterozygous carriers could place them at an elevated risk of tumorigenesis. The parents of individuals presenting with *FH* recessive disorders often develop tumors.[@bib24] For heterozygous carriers of mutations in the different *SDH* genes associated with infantile neurological presentations, the situation is unclear. Although there is no indication of cancer susceptibility in either family with *MDH2* mutations, we are recommending ongoing surveillance and screening.

In conclusion, we have shown that bi-allelic variants in *MDH2*, encoding a mitochondrially targeted Krebs cycle enzyme, are responsible for a severe infantile neurological phenotype. Although the clinical presentation and elevated lactate concentrations are highly evocative of mitochondrial disease, there are no specific biomarkers to pinpoint the rapid diagnosis of MDH2 deficiency, and as such, gene-panel or whole-exome sequencing analysis will not only be important for diagnosing further cases but also allow the detection of heterozygous carriers, thus determining their risk of tumorigenesis.
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![*MDH2* Mutations in Three Unrelated Affected Subjects\
(A) Pedigrees and sequence chromatograms showing variant phenotypes and segregation through the subjects' families.\
(B) Cross-species conservation of the MDH2 sequence flanking the altered Gly37, Pro133, and Pro207 amino acids.\
(C) Three-dimensional representation of the crystal structure of human MDH2 (PDB: [2DFD](pdb:2DFD){#intref0130}, residues 24--337), shown as a homodimer with one molecule in gray and a second in yellow. Green and fuchsia sticks illustrate malate ions and NAD, respectively. The mutated residues are highlighted in black (Gly37), orange (Pro133), and red (Pro207).](gr1){#fig1}

![*MDH2* Mutations Cause Loss of MDH2 Levels and Enzymatic Activity\
(A) Western blot analysis with anti-MDH2 antibodies in fibroblasts from subject 1 (S1, top) and subject 3 (S3, bottom). Additional abbreviations are as follows: C1--C3, control individuals; M, mother of S1; and F, father of S1. Commercial MDH2-specific antisera at 1:250 (HPA019716, Sigma-Aldrich) or 1:1,000 (8610S, Cell Signaling Technology) were used for the upper and lower panels, respectively. GAPDH and α-tubulin were used as loading controls.\
(B) Representation of MDH2 activity, measured with the Mitochondrial Malate Dehydrogenase (MDH2) Activity Assay Kit (Ab119693, Abcam), in the fibroblasts from S1, his parents, and control individuals (top) and in those from S3 and control individuals (bottom). Data represent three independent experiments performed in duplicate.\
(C) Schematic of the Krebs cycle.\
(D) Metabolite ratios assessed by liquid chromatographic tandem-mass spectrometry in fibroblasts from S1 are compared with those from his parents and control individuals. Experiments were performed as previously described.[@bib4] Differences between fibroblast cells were analyzed by Student's t test: ^∗∗∗^p \< 0.001 (extremely significant).](gr2){#fig2}

![Functional Complementation Showing the Pathogenicity of MDH2 Variants\
(A and B) Functional complementation of fibroblasts. The human full-length *MDH2* cDNA was cloned into the pHR-SIN-CSGW dlNotI vector by PCR ([Table S3](#mmc1){ref-type="supplementary-material"}). Lentiviral particles were produced in HEK293T cells. Then, fibroblasts were infected with viral supernatant expressing either *MDH2* cDNA or eGFP (as a control). (A) Restoration of MDH2 levels in S1 fibroblasts transduced with wild-type *MDH2* cDNA as determined by western blot with anti-MDH2 antibody. No restoration was observed when cells were transduced with GFP cDNA (C, non-transduced control fibroblasts). (B) Restoration of MDH2 activity in S1 fibroblasts transduced with wild-type *MDH2* cDNA (two independent experiments performed in duplicate). No restoration was observed when cells were transduced with GFP cDNA. The MDH2 activity of non-transduced fibroblasts from parents and a control individual is also shown.\
(C) Functional complementation assay of the yeast *mdh1Δ*-null mutant. Human *MDH2* cDNA was amplified with the corresponding primers ([Table S3](#mmc1){ref-type="supplementary-material"}) and cloned into the centromeric expression plasmid pYX122 (constitutive promoter *TPI*, Addgene). The yeast wild-type *MDH1* and the *mdh1* mutated sequences corresponding to the three missense mutations were obtained by PCR ([Table S3](#mmc1){ref-type="supplementary-material"}), and the corresponding fragments were introduced into the linearized pYX122 vector by co-transformation of the *mdh1Δ* strain (BY4741, Open Biosystems) and homologous recombination. Plasmids from the transformants were extracted and sequenced. These plasmids were then reintroduced into the *mdh1Δ* strain for testing their complementation capability. Growth of *mdh1Δ* (−) transformed with wild-type *MDH1*, mutated *mdh1-P128L*, *mdh1-P202L*, or *mdh1-G30R*, or wild-type *hMDH2* plasmids was tested either on glucose (YPD, fermentable carbon source) or on glycerol (YPG, non-fermentable carbon source). Drop dilution growth tests were performed at 1/10 dilution steps and incubated on YPD or YPG plates for 2 days at 28°C or 35°C.](gr3){#fig3}

###### 

Genetic and Clinical Findings in Subjects with Bi-allelic *MDH2* Variants

                                          **Subject 1**                                                                                                                                                  **Subject 2**                                                                                           **Subject 3**
  --------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------
  Gender                                  male                                                                                                                                                           male                                                                                                    male
  Family history                          no                                                                                                                                                             no                                                                                                      no
  Consanguinity                           no                                                                                                                                                             no                                                                                                      no
  Age at last clinical examination        4.5 years                                                                                                                                                      died at 1.5 years                                                                                       7.5 years (lost view)
  *MDH2* mutations                        c.398C\>T (p.Pro133Leu)                                                                                                                                        c.398C\>T (p.Pro133Leu)                                                                                 c.109G\>A (p.Gly37Arg)
  c.620C\>T (p.Pro207Leu)                 c.596delG (p.Gly199Alafs^∗^10)                                                                                                                                 c.398C\>T (p.Pro133Leu)                                                                                 
  Age at onset                            5 months                                                                                                                                                       neonatal                                                                                                neonatal
  Initial symptom                         hypotonia, no head control                                                                                                                                     seizures                                                                                                hypotonia
  Refractory epilepsy                     \+ (partial, afterward myoclonic; onset at 7 months)                                                                                                           \+ (generalized tonic and spasms; onset at 2 months)                                                    \+ (myoclonic epilepsy and generalized tonic; onset ?)
  Hypotonia                               \+ (marked, mainly axial and in the lower limbs)                                                                                                               \+ (axial)                                                                                              \+
  Developmental delay                     \+                                                                                                                                                             \+                                                                                                      \+
  Head control                            10 months                                                                                                                                                      not acquired at 6 months                                                                                12 months
  Sitting position                        18 months                                                                                                                                                      not acquired at 12 months                                                                               −
  Crawling                                18 months                                                                                                                                                      not acquired at 12 months                                                                               no
  Good eye contact                        yes                                                                                                                                                            yes                                                                                                     no
  Language                                not acquired                                                                                                                                                   babbling at 12 months                                                                                   not acquired
  Muscle weakness                         \+                                                                                                                                                             \+                                                                                                      \+
  Failure to thrive                       \+                                                                                                                                                             −                                                                                                       \+
  Age at onset                            7 months                                                                                                                                                       −                                                                                                       ?
  Gastrostomy (age)                       \+ (3 years)                                                                                                                                                   −                                                                                                       \+ (?)
  Last examination                        4 years                                                                                                                                                        18 months                                                                                               7.5 years
   Length                                 \< −2 SDs                                                                                                                                                      \+ 1 SD                                                                                                 −2 SDs
   Head circumference                     \< −2 SDs                                                                                                                                                      \+ 1 SD                                                                                                 +2 SDs
   Weight                                 \< −3 SDs                                                                                                                                                      \+ 1 SD                                                                                                 −2.5 SDs
  Movement disorders                      dystonia and dyskinesia                                                                                                                                        −                                                                                                       dystonia
  Obstinate constipation                  \+                                                                                                                                                             \+                                                                                                      −
  Ophthalmologic examination (age)        retinitis pigmentosa (4 years), strabismus (5 months)                                                                                                          strabismus (1 year)                                                                                     ?
  Pyramidal signs                         \+                                                                                                                                                             \+                                                                                                      −
  Deep tendon reflexes                    decreased                                                                                                                                                      N                                                                                                       −
  Plantar responses                       bilateral extensor                                                                                                                                             bilateral extensor after 1 year                                                                         normal
  Other findings                          −                                                                                                                                                              −                                                                                                       two supernumerary nipples, von Willebrand disease, CCAM
  Ketogenic diet (onset)                  \+ (3 years)                                                                                                                                                   \+ (18 months)                                                                                          \+ (3 years)
  Response to Ketogenic diet              reduction epileptic seizure frequency                                                                                                                          reduction epileptic seizure frequency                                                                   ?
  Evolution                               alive at 5 years                                                                                                                                               died at 1.5 years (secondary to metabolic decompensation)                                               alive at 12 years
  Brain MRI abnormalities                 \+ (atrophy of the anterior part of the CC, delayed myelination of the frontal white matter, frontal and parietal atrophy, elevated lactic acid peak on MRS)   \+ (delayed myelination of the genu of the CC, cortical and subcortical atrophy of the frontal lobes)   \+ (cerebral cortical and subcortical atrophy, cerebellar atrophy, elevated lactic acid peak on MRS)
                                                                                                                                                                                                                                                                                                                 
  **Lactate Concentration**                                                                                                                                                                                                                                                                                      
                                                                                                                                                                                                                                                                                                                 
  Plasma (N \< 2.20 mmol/l)               elevated (3.0)                                                                                                                                                 elevated (5.7)                                                                                          elevated (2.8)
  L/P ratio (N \< 18)                     elevated (63)                                                                                                                                                  elevated (23)                                                                                           elevated (20)
  CSF (N \< 2.10 mmol/l)                  elevated (2.48)                                                                                                                                                elevated (3.3)                                                                                          ND
                                                                                                                                                                                                                                                                                                                 
  **Krebs Cycle Intermediates**                                                                                                                                                                                                                                                                                  
                                                                                                                                                                                                                                                                                                                 
  Malate (N \< 7 μmol/mmol creatine)      elevated (56)                                                                                                                                                  elevated (15--38)                                                                                       ND
  Fumarate (N \< 14 μmol/mmol creatine)   elevated (20)                                                                                                                                                  N or elevated (9--55)                                                                                   N
  Succinate                               N                                                                                                                                                              N                                                                                                       N
                                                                                                                                                                                                                                                                                                                 
  **RC Activity**                                                                                                                                                                                                                                                                                                
                                                                                                                                                                                                                                                                                                                 
  Muscle                                  N                                                                                                                                                              ND                                                                                                      N
  Liver                                   reduced CV activity                                                                                                                                            ND                                                                                                      ND
  Fibroblasts                             N                                                                                                                                                              ND                                                                                                      reduced CI activity

Abbreviations are as follows: +, present; −, absent; ?, unknown; N, normal; ND, not done; SD, standard deviation; CCAM, congenital cystic adenomatoid malformation; MRS, magnetic resonance spectroscopy; CC, corpus callosum; L/P, lactate/pyruvate; CSF, cerebrospinal fluid; RC, respiratory chain; CV, complex V; and CI, complex I.
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